Trial NCT05411094

View at ClinicalTrials.gov 
Org. Study IDs: NCI-2022-04526
Secondary IDs: 10464 NCI-2022-04526 P30CA046592 UMCC 2021.037

Last trial update was posted on 2024-04-08

MeSH Interventions

Antibodies, Monoclonal Durvalumab Immunoglobulin G Immunoglobulins Olaparib Poly(ADP-ribose) Polymerase Inhibitors

MeSH Conditions

Carcinoma Pancreatic Neoplasms

Other Conditions

Locally Advanced Pancreatic Carcinoma Stage II Pancreatic Cancer AJCC v8 Stage III Pancreatic Cancer AJCC v8 Unresectable Pancreatic Carcinoma

Stopping Reasons

Scheduled Interim Monitoring

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID